NPI registry status
Active
2026 NPPES data Hematology & Oncology Physician NPI 1962475509
Verify on CMS → Anastasios Raptis
Hematology & Oncology Physician in Pittsburgh, Pennsylvania.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,232 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
2K
Medicare Part D claims · 158 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
76%
generic claims · 23% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
75/100
CMS neutral threshold · no category scores published
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Anastasios Raptis carries the neutral CMS MIPS final score of 75/100, assigned where no category was scored - and filed 1,704 Medicare Part D claims in 2023.
- 75/100
- CMS neutral score · not measured
- 2K
- Part D claims, 2023
- 76%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Anastasios Raptis's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023, across all CMS prescribers nationally
1,704 ≥ 83rd percentile 83% of 1,370,886 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2023
✓
Board certification likely (heuristic, not verified)
Anastasios Raptis practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Anastasios Raptis?
CMS neutral score, not measuredPrimary specialty
Hematology & Oncology Physician
Medicare Part D claims
1,704 101% vs specialty avg
MIPS final score
75/100
Specialty distribution in Pennsylvania
How Hematology & Oncology Physician compares to other specialties among Pennsylvania providers
MIPS score not measured
CMS assigned a neutral 75/100 threshold
CMS did not publish any Quality, Cost, Promoting Interoperability, or Improvement Activities category score for this clinician. This administrative threshold is not comparable with the national average of clinicians whose MIPS score was measured.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Anastasios Raptis appears in the CMS NPPES registry as a Hematology & Oncology Physician provider at 5115 CENTRE AVE, Pittsburgh, PA, 15232, with a listed phone of (412) 864-6600. NPI 1962475509 was issued on 02/13/2006.
Medicare Part D records for calendar year 2023 show 1,704 prescription claims written by this provider, covering 158 Medicare beneficiaries and totaling roughly $4.4 million in drug spend, split 23% brand-name and 76% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider carries a Final Score of 75/100 for the 2023 performance year, but CMS published no Quality, Promoting Interoperability, Improvement Activity or Cost score: this is the neutral performance threshold CMS assigns where nothing was scored, so it is not comparable with clinicians whose score was measured.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,232 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1962475509 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Gender | Male |
| NPI Issued | 02/13/2006 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
75
Final Score
CMS neutral threshold · not measured
Reporting: Group practice
Hospital and facility affiliations
Facilities where Anastasios Raptis bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Oncology Hematology Association Inc
Pittsburgh, PA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context - Pennsylvania PA-BOM 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~45K Pennsylvania medical licensees in 2023 - they are NOT specific to Anastasios Raptis. To verify Anastasios Raptis's current license status, search the PA-BOM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
133
Total board actions, Pennsylvania 2023
Across 129 cases
2.96
Actions per 1,000 licensees
Pennsylvania statewide rate
probation
Most common action type
48 cases
PA-BOM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Pennsylvania disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
Anastasios Raptis - brand share 23.0%
Hematology & Oncology Physician average
23% brand-name claims vs 76% generic, on 1,704 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
1,704
Total Claims
$4.4M
Total Drug Cost
158
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,994
- Total Day Supply
- 53,386
- Brand vs Generic
- 23% brand / 76% generic
- Brand Drug Cost
- $4.1M
- Generic Drug Cost
- $309K
- Antibiotic Claims
- 98
Patient Demographics
- Average Patient Age
- 72.2 years
- Avg HCC Risk Score
- 3.04
- Gender Split
- 51% female / 49% male
- Age Distribution
- <65: 20, 65-74: 81, 75-84: 41, 85+: 16
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Anastasios Raptis prescribes most
Top Medicare Part D drugs by claim count, 2023
- Acyclovir
Acyclovir
284 claims
- Allopurinol 108
Allopurinol
108 claims
- Dexamethasone 90
Dexamethasone
90 claims
- Potassium Chloride 89
Potassium Chloride
89 claims
- Pantoprazole Sodium 81
Pantoprazole Sodium
81 claims
- Fluconazole 79
Fluconazole
79 claims
- Ninlaro 59
Ninlaro
59 claims
- Pomalyst 50
Pomalyst
50 claims
| Drug | Claims |
|---|---|
| Acyclovir | 284 |
| Allopurinol | 108 |
| Dexamethasone | 90 |
| Potassium Chloride | 89 |
| Pantoprazole Sodium | 81 |
| Fluconazole | 79 |
| Ninlaro Ixazomib Citrate | 59 |
| Pomalyst Pomalidomide | 50 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 48 |
| Ondansetron Hcl | 47 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Anastasios Raptis fits within the Hematology & Oncology Physician landscape nationally.
11,232
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider
Anastasios Raptis's 1,704 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in Pennsylvania
Other clinicians with the same primary specialty enrolled in Pennsylvania, drawn from the same CMS NPPES roster as Raptis.
Dr. Abdullateef Abdulkareem
M.D.
Lancaster, PA
Dr. Charles Abrams
MD
Philadelphia, PA
Tala Achkar
Pittsburgh, PA
Dr. Monica Adedeji
MD, MPH
Hershey, PA
Dr. Giridhar Adiga
MD
Ephrata, PA
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Pennsylvania medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore Pennsylvania
Frequently Asked Questions
What is Anastasios Raptis's specialty? ▼
Anastasios Raptis specializes in Hematology & Oncology Physician and practices in Pittsburgh, Pennsylvania.
How much does Anastasios Raptis prescribe under Medicare Part D? ▼
In 2023, Anastasios Raptis wrote 1,704 Medicare Part D claims totaling $4.4M in drug costs for 158 beneficiaries.
What is Anastasios Raptis's Medicare quality score? ▼
Anastasios Raptis has a CMS MIPS Final Score of 75/100. CMS published no Quality, Promoting Interoperability, Improvement Activity or Cost score for this clinician, so the final score is the neutral performance threshold CMS assigns rather than a measured result. The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Anastasios Raptis located? ▼
Anastasios Raptis is located at 5115 CENTRE AVE, Pittsburgh, PA, 15232. Phone: (412) 864-6600.
What is Anastasios Raptis's NPI number? ▼
Anastasios Raptis's National Provider Identifier (NPI) is 1962475509, issued on 02/13/2006.
Does Anastasios Raptis prescribe more brand-name or generic drugs? ▼
Anastasios Raptis's prescribing is 23% brand-name and 76% generic drugs by claim count, with $4.1M in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US? ▼
There are 11,232 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does Anastasios Raptis prescribe most often? ▼
Based on 2023 Medicare Part D data, Anastasios Raptis's most frequently prescribed drugs include Acyclovir, Allopurinol, Dexamethasone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Anastasios Raptis accept Medicare? ▼
Anastasios Raptis appears in CMS Medicare data with 1,704 Part D claims and 158 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Anastasios Raptis's credentials? ▼
Anastasios Raptis's NPI is 1962475509. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.